
    
      Subjects will be randomly assigned to a diet. They will at onset have hemoglobin A1c values
      between 5.7% and 6.4%. Baseline glucose tolerance test will be performed, as well as measures
      of inflammation and fecal microbiome. Interim tests will be performed at six weeks. Subjects
      will participate for 12 weeks, at which time they will be re-evaluated.
    
  